Jonathan Rigby is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he established SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. As the CEO, he led the company through a Nasdaq listing in 2015 (Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR) in late 2018.
In 2006 he co-founded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical.
Jonathan has served as Executive Board Member at SteadyMed Ltd, (Nasdaq: STDY), Non-Executive Board Member at Xeris Pharmaceuticals (Nasdaq: XERS) and Chairman of the Board at CollPlant Biotechnologies, (Nasdaq: CLGN). He has a Bachelor of Science Degree, with Honours, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.